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INTRODUCTION AND AIMS. OF THE DISSERTATION: 
Since the 1970s, relatively uncommon species of non-enteric gram-negative 
bacilli have emerged as nosocomial colonizers and pathogens. Among them, one 
of the most significant genera is Acinetobacter, which has given rise to an 
increasing number of reports of nosocomial infections [9, 13 , 25, 41]. 
The introduction of new broad-spectrum antimicrobials in the hospitals has been 
one of the main factors responsible for this development. In addition leading to a 
move from more susceptible towards more resistant pathogens. This occurred 
both between and within genera [38]. 
Owing to the unpredictable antimicrobial susceptibility of Acinetobacter spp ., it 
is prudent to test each isolate for its susceptibility profile to guide in the proper 
treatment of infections caused by Acinetobacter. 
The disk diffusion method is the technique most widely used by microbiology 
laboratories for the routine assessment of antimicrobial susceptibility patterns. 
The zone diameters obtained by this technique for individual antimicrobials are 
reported as susceptible, intermediate or resistant by referring to an interpretative 
chart. Most laboratories use interpretative charts (zone size criteria) supplied by 
the National Committee for Clinical Laboratory Standards (NCCLS) for this 
purpose [31]. 
In our laboratory we have noted discrepancies between sensitivities as 
determined by the NCCLS zone size criteria and the local minimum inhibitory 
concentration (MIC) results obtained for Acinetobacter species, especially for 
cefepime (CPIM) and ceftazidime (CT AZ) . 
• ... 
Since Acinetobacter species contribute significantly to the increased morbidity 
and mortality of debilitated patients ( especially ventilated ICU patients [ 19, 25]), 
and the fact that clinicians rely on the antimicrobial susceptibility results in the 
management and treatment of these patients, it was felt necessary to investigate 
the appropriateness/validity of the NCCLS zone size criteria used to interpret the 
susceptibility test results of cefepime (CPIM), ceftazidime (CT AZ), 
trimethoprim-sulfamethoxazole (TMP-SULF A), and piperacillin-tazobactam 
(PIP-T AZO) against Acinetobacter spp. 
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LITERATURE REVIEW: 
[Al THE ORGANISM 
Acinetobacter spp. are short, plump gram-negative (but sometimes difficult to 
decolourise) coccobacilli, with a "DNA G+C content of 39 to 47 mo!% . They 
appear rod shaped during rapid growth and as coccobacilli during the stationary 
phase. Cells do not form spores, are. generally encapsulated and non-motile 
(from which they derive their name) . They do however display "twitching 
motility" presumably because of the presence of polar fimbriae . They are strictly 
aerobic, non-fermentative bacteria that grow well on all common complex media 
at temperatures between 20°C and 30°C, with most strains having an optimum 
temperature of 33°C - 35°C. They are oxidase negative and catalase positive. 
Acinetobacter is widespread in nature, being found in soil, water and sewage [8, 
18]. 
Taxonomy: 
After a colourful history the genus Acinetobacter was originally placed in the 
family Neisseriaceae , but was more recently moved to the family Moraxellaceae . 
Gram-negative, nonfermentative bacteria currently recognized as belonging to 
the genus Acinetobacter have been classified previously under at least 15 
different 'generic' names, the best known of which are Bacterium anitratum; 
Herellea vaginicola; Mima polymmpha; Achromobacter; Alcaligenes; 
Micrococcus calcoaceticus; BSW; Moraxefla glucidolytica and Moraxella 
lwoffii [8, 44] . 
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The taxonomy of Acinetobacter ha.s changed fr~quently . Up to now 21 genomic 
species (DNA-DNA homology groups) have been described. Some of the 
species have formal names: ·group 1 = A.calco"aceticus; group 2 = A.baumanii; 
group 4 = A.haemolyticus; group 5 = A.junii; group 7 = A johnsonii; group 8 
= A.lwoffii and group 12 = A.radioresistens, while the rest are unnamed. 
There is a close relationship between the genomic species 1 (A.calcoaceticus) , 2 
(A. baumanii), 3 and 13 of Tjernberg and Ursing, which are sometimes named as 
the A.calcoaceticus-A.baumanii complex [13] . 
Clinically the most important species is A.baumanii. In one study that included 
584 clinical Acinetobacter isolates, 72.9% of the isolates were identified as 
A.baumanii, and the remaining 27 .1 % of the strains is6lated belonged to other 
species, of which the most frequent were Acinetobacter genomic species 3 
(9.4%), A.johnsonii (5 .0%) and A.lwoffii (6 .3%) [13]. 
Laboratory Identification: 
Isolation from clinical specimens. 
Acinetobacter spp. can be readily grown on common laboratory media such as 
nutrient agar. However, for direct isolation from clinical specimens, it is more 
useful to use a selective me~ium to suppress the growth of other 
microorganisms. A selective and di~erential medium containing bile salts, sugars 
and bromocresol purple is available commercially as Herellea agar (Difeo) . A 
novel antimicrobial-containing selective medium that combines selectivity with 
differential characteristics has been described, and this medium, Leeds 
Acinetobacter Medium, is useful for the recovery of most Acinetobacter spp. 
from both clinical and environmental ~ources [20]. 
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Acinetobacter colonies are smooth, opaque and slightly smaller than those of 
members of the family Enterobacteriaceae . Many strains grow on MacConkey 
agar as either colourless or slightly pinkish colonies. 
All members of the genus are stric,t aetobes, oxidase negative, and catalase 
positive and nonfermentative. It is the negative oxidase test that serves as a 
rapid presumptive test to distinguish Acinetobacter spp. from otherwise similar 
nonfermentative bacteria [39]. 
Species Identification. 
Several different DNA-hybridisation methods can be used to identify the 
different genomic species, but these methods are laborious and unsuitable for use 
in the routine microbiology laboratories. 
Sixteen of these 21 DNA-homoiogy groups can be differentiated by means of 
biochemical and growth tests [39]. These phenotypic tests include tests for 
growth at 30°C, 3 7°C, 41 °C and 44°C, glucose oxidation, gelatin liquefaction, 
haemolysis on 5% sheep blood agar plates and carbon source assimilation tests . 
When referring to strains of DNA groups 1, 2, 3 and 13 of Tjernberg and Ursing, 
it seems more appropriate at present to use the expression A. calcoaceticus-
A. baumanii complex, and if there is a need for differentiation within this complex 
the biotyping system suggested for A. baurnanii may be used [ 16]. 
Simply and practically most glucose oxidizing non-haemolytic clinical strains that 
can grow at 44°C are A.baumanii; most glucose-negative non-haemolytic strains 
are A.lwoffii and most haemolytic strains are A.haemolyticus [39]. 
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As far as the commercial identification systems are concerned, the widely used 
API 20NE system, based largely on carbon source assimilation tests contained 
only A.baumanii, A.haemolyticus, and A.lwoffii in its 1996 database, together 
with A.junii and A.johnsonii as a combination, whereas the type species 
A.calcoaceticus and the other genomic species were not included at all . 
Problems in respect of sensitivity and reproducibility have been experienced 
when using this system [24] . 
Several studies comparing the API 20NE system with species identification by 
DNA-DNA hybridisation have demonstrated a poor correlation [ 46]. 
Phenotypic identification methods for individual Acinetobacter species are not 
totally reliable, and this can be a source of confusion in clinical microbiology 
laboratories. To avoid the problems with phenotypic species identification, new 
molecular identification methods are currently being evaluated against DNA-
DNA hybridisation. 
Epidemiology and Pathogenesis: 
Epidemiology. 
Ac;netobacter is widely spread in nature, being found in soil and water and 
frequently present in the hospital environment. Being non-fastidious and hardy 
they can survive on moist and on dry surfaces. After experimental contamination 
of fingers A. baumanh survived 60 minutes . Longer survival times were not 
examined, but on dry Formica surfaces A.calcoaceticus survived up to 13 days 
[13]. 
Adnetobacter spp. are part of the normal flora of human skin and can be isolated 
from the axillae, groin, toe webs, and antecubital fossae of about one fourth of 
the population. Oropharyngeal or rectal carriage is rare. Acinetobacter spp. has 
been found on the hands of 19% of hospital personnel and may be regarded as 
part of the non-transient flora [ 17]. 
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Non-transient Acinetobacter and other gram-negative bacilli on the hands of 
hospital personnel are thus a potential reservoir of hospital strains. 
In outbreak situations colonization rates of the respiratory tract, the pharynx, the 
skin, the urinary tract and the gastrointestinal tact of patients may be high. Hand 
carriage in outbreaks was reported to be transient; transmission of an epidemic 
strain from the patient skin to the staff member hands has been demonstrated 
experimentally. A decline in the incidence of hand carriage occurred after 
reinforcement of strict hand washing procedures [ 13, 14]. 
From a study by Allen & Green [ 4] it was concluded that airborne Acinetobacter 
could produce extensive environmental contamination, and the possibility of 
airborne spread should be considered in future outbreaks. 
In an outbreak of Acinetobacter spp. meningitis in leukaemic children it was 
determined that the methotrexate was extrinsically contaminated by reused 
needles, used for reconstitution and administration, which had been inadequately 
sterilized. After the introduction of single-use disposable needles no subsequent 
cases occurred [22]. 
In a recent investigation of an outbreak ~f nosocomial Acinetobacter infection, 
the respiratory and anaesthetic equipment and staff hands were originally 
suspected of being the source and mode of spread (the most common sources in 
ICUs) but after hygienic procedures were improved, the outbreak did not come 
to an end. This suggested that the patients were exposed to multiple sources, 
and the bedding was suspected, leading to an investigation of feathered pillows. 
These were found to be contaminated with considerable numbers of 
Acinetobacter spp. Replacement with synthetic pillows and correction of the 
laundry procedure resulted in a significant reduction of Acinetobacter spp. 
isolations [ 46]. 
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Contamination of mattresses was also found as the cause for an outbreak of 
Acinetobacter infections in burn patients [ 40]. 
The above examples illustrate the ubiquitous nature of Acinetobacter spp. and 
the difficulty of establishing the reservoir of infection in many instances. This 
survival in the inanimate environment can serve as a ·reservoir for continuous 
I 
contamination of hands. 
However "hand carriage from contact with infected patients is the most likely 
mode of transmission, although staff hand contamination from inanimate objects 
may also be an important factor" [ 13]. 
From July 1974 through December 1977 180,982 nosocomial infections were 
reported to the CDC (Center for Disease Control), among these Acinetobacter 
spp. were identified as the pathogen in 1,372 (0 .76 %). Even though the overall 
rates of nosocornial infections caused by Acinetobacter spp. were stable each 
year, there was a dramatic seasonal fluctuation; the rate of infection was twice as 
high in late summer as in the early winter. The same seasonal increase was 
observed in medical and surgical services and at all major sites of infection. The 
reasons for this phenomenon are unclear, but they may be related to increased 
ambient humidity favorable for this organism's growth [35]. 
McDonald et al [27] also documented this seasonal pattern as observed from 
1987 through 1996. But in the SENT~Y Antimicrobial Surveillance Program 
(1997-1999) [ 15], it was noticed that this seasonal pattern was lacking in Latin 
America. Many reasons could account for the lack . of this pattern in Latin 
America, such as the persistence of endemic strains in some medical centres 
allowing the occurrence of clustered epidemic Acinetobacter infections 
throughout the year, or an insufficient number of strains collected monthly in the 
SENTRY program to clarify seasonal prevalence. 
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Typing methods are important tools for establishing the sources and mode(s) of 
transmission for epidemic strains. There are a number of typing systems, which 
include: biotyping, using biochemical profiles; antibiograms, which uses 
antibiotic susceptibility patterns; serotyping; phage typing; bacteriocin typing; 
protein profiles of both cell wall and whole cell proteins; multilocus enzyme 
electrophoretic typing which investigates the relative mobilities of a large 
number of cellular enzymes; plasmid profiles; analysis by pulse field gel 
electrophoresis of restriction fragment length polymorphism; and ribotyping. 
No single typing system has so far gained acceptance for typing Acinetobacter 
spp., and this area is still the subject of research [8]. 
Pathogenesis: 
Acinetobacter spp. are generally considered to be relatively non-pathogenic to 
healthy individuals, but despite this low pathogenic potential they are 
increasingly reported as the causal organism of numerous hospital outbreaks. 
Various risk factors predisposing to severe infection with Acinetobacter spp. 
have been identified. These risk factors include patients who have recently 
undergone major surgery, tho~e with seve~e underlying disease, use of 
antimicrobial agents, presence of invasive devi~es, and those at extremes of age. 
Since the only factor amenable to control in the ICU setting is antimicrobial 
therapy, avoidance of unnecessary antimicrobials should be a high priority in 
management of such patients. The use of antimicrobials may alter the normal 
flora and result in the selection of resistant microorganisms such as 
Acinetobacter spp. 
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Certain characteristics of Acinetobacter spp. may enhance the virulence of 
strains involved in infections. These characteristics include (i) the presence of a 
polysaccharide capsule; (ii) the property of adhesion to human epithelial cells is 
related to the presence of fimbriae and/or capsular polysaccharide; (iii) the 
production of enzymes which may damage tissue lipids; and (iv) the potentially 
toxic role of the lipopolysaccharide component of the cell wall and the presence 
of lipid A. The production of endotoxin in-vivo is probably responsible for the 
disease symptoms observed during Acinetobacter septicaemia [ 44]. 
Nosocomial infections: 
Acinetobacter spp. have emerged as particularly importart organisms in ICUs, 
and this is probably related to the widre use of antimicrobial agents, and the 
increasing use of invasive diagnostic and therapeutic procedures in hospital 
ICUs. 
The true frequency of nosocomial infect.ion caused by Acinetobacter spp. is not 
easy to assess, partly because the isolation of these organisms from clinical 
specimens may not necessarily reflect infection but, rather, may result from 
colonization [ 41]. According to data fro·m the National Nosocomial Infections 
Surveillance (NNIS) system from 1990-1992, Acinetobacter spp . were isolated 
in 1 % of all nosocomial infections [ 13]. 
The most common site of nosocomial infections caused by Acinetobacter spp. is 
the respiratory tract, especially in ventilated patients, with a crude mortality rate 
of 30% to 75% reported [9]. This is followed by bacteremia, with A.baumanii 
being the most commonly isolated of the Acinetobacter spp. Debilitated patients 
make up the largest group of adult patients. 
A second important group of patients is neonates [3 2, 3 7]. 
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Less frequently, the urinary tract, surgical wounds, the central nervous system, 
the peritoneum, burn wounds, and the eyes are involved [13]. 
Acinetobacter cholangitis and septic complications following percutaneous 
transhepatic cholangiogram and . percutaneous biliary drainage have been 
reported [36]. 
Although community-acquired Acinetobacter infections are relatively 
uncommon, Anstey and co-workers reported that l 0% of cases of community-
acquired pneumonia in the Northern Territory of Australia were caused by 
Acinetobacter spp. [6]. 
Antimicrobial susceptibility and Treatment: 
The genus Acinetobacter is an environmental organism, which seems to have a 
propensity to develop antimicrobial resistance very rapidly, compared to the 
more traditional pathogenic . bacteria, which require more time to acquire highly 
effective resistance mechanisms in response to antimicrobial exposure. 
Until the early 1970s, nosocomial Acinetobacter spp. were amenable to 
treatment with ~-lactams, aminoglycosides and quinolones, either as single 
agents or in combinations. Since 1975 nosocomial Acinetobacter spp., 
especially A. baumanii, have become increasingly resistant to clinically achievable 
levels of most commonly used antimicrobial agents. 
Resistance to the ~-lactams is mainly due to the production 9f ~-lactamases [33], 
in addition to the reduced permeability of the outer membrane proteins of 
Acinetobacter spp. and the low affinity of their penicillin binding proteins. 
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Aminoglycoside resistance has also been reported, due to altered permeability, 
lack of intracellular antimicrobial binding sites and to the presence of 
aminoglycoside modifying enzymes [12]. 
As a result, the broad-spectrum cephalosporins (cefepime and ceftazidime), 
fluoroquinolones, carbapenems and amikacin have become the mam 
antimicrobials of empiric choice to treat A. baumanii infections. Recently 
quinolone resistance due to gyr A-mutatton has been ' frequently reported [ 45] , . 
and more recently carbapenem resistant A. baumanii are being increasingly 
reported [2, 10, 43]. 
This emerging resistance among Acinetobacter spp. has made the empiric choice 
of an effective antimicrobial agent increasingly difficult. In addition to this 
emerging resistance there are significant differences in the Acinetobacter 
antibiograms, depending on the species and the region of isolation, i.e. the 
antibiogram for Acinetobacter spp. is unpredictable, hence the necessity for 
reliable susceptibility testing methods to predict the clinical response. 
Numerous reports in the medical and scientific literature have documented the 
high rates of antimicrobial resistance found in Acin~tobacter spp. [ 41]. 
In our laboratory we have also noticed an increased number of Acinetobacter 
spp. developing resistance to almost all the currently available antimicrobials. 
A particular concern has been the increase in the number of nosocomial 
Acinetobacter isolates found resistant to multiple antimicrobial agents, and the 
resulting therapeutic problems involved in treating patients with nosocomial 
infections in the ICUs. 
Most of the newly developed antimicrobial agents are effective against gram-
positive organisms. The development of new agents directed against gram-
negative organisms is extremely important and, in the interim, seeking the best 
agents among the current and older compounds is the only option [ 15]. 
... 
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As such, treatment must be individl,lalized · depending on the antimicrobial 
sensitivity results of each isolate in-vitro . 
Species other than A. baumanh, i.e. A.lwoffii , A.johnsonii, and A.junii, are 
involved less frequently in nosocomial infection and are generally more 
susceptible to antimicrobials. 
[Bl IN-VITRO ANTIMICROBIAL SUSCEPTIBILITY TESTING: 
The need to know whether an organism is likely to respond to antimicrobial 
therapy is as old as chemotherapy itself 
Fleming reported the inhibitory effect of what eventually became known as 
penicillin on solid media by observing an area of growth inhibition of 
staphylococcal colonies adjacent to a Penicillium contaminant on an agar plate. 
This, however, was not the first description of what was eventually termed agar 
diffusion, as this was first utilized by Beijerinck in 1889 for studying the effect of 
different auxins on bacterial growth. But Fleming in 1924 introduced the use of 
the ditch plate technique for evaluating antimicrobial qualities of antiseptic 
solutions. Reddish modified this technique when he cut wells into the agar and 
filled the wells with antiseptic solutions. In 1940, Heatly introduced the use of 
absorbent paper for carrying antimicrobial solutions. 
Mohs introduced a 'radial streak disk method ' with 15mm diameter disks. This 
was the first description of the comparison of a test organism with a sensitive 
control on the same plate. This method was the forerunner of the Stokes' 
technique, which until recently was still used in many laboratories in the UK. 
More paper disk diffusion methods were described in the mid- l 940s. 
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Fleming' s second contribution to modern antimicrobial susceptibility testing was 
the development of a broth dilution technique using turbidity as an end-point 
determination, which was the forerunner of contemporary MIC methodology. 
Schmith and Reymann were the first to describe an agar dilution antimicrobial 
susceptibility testing method [ 4 7] . 
At an early stage it became apparent to workers using diffusion and dilution 
techniques that there were many variables affecting antimicrobial susceptibility 
testing methods. By the end of the· 1950s it was apparent that there was a need 
to standardize antimicrobial susceptibility testing. Several organizations and 
investigators began addressing this critical issue. 
In 1966, significant progress in standardization of the disk method occurred 
when Bauer, Kirby and co-workers published their attempt to establish the disk 
diffusion technique as a practical method of testing with a broad application to 
clinical laboratories. In 1975, this method became the basis of the NCCLS disk 
diffusion standards [ 4 7] . 
The primary function of in-vitro antimicrobial susceptibility testing in clinical 
laboratories is to provide information to prescribers on the choice of appropriate 
chemotherapy, whether it be for therapy or prophylaxis in specific patients, or to 
help in antimicrobial policy formulation . 
Disk diffusion tests based solely on the presence or absence of a zone of 
inhibition without regard to the size of the zone are not acceptable. Reliable 
results can only be obtained with disk diffusion tests that use the principle of 
standardized methodology and zone diameter measurements . The outer limit of 
the zone of inhibition contains an antimicrobial· concentration, which is similar to 
the MIC of that antimicrobial to a specific organism. 
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The zone diameters for individual antimicrobials are reported as susceptible, 
intermediate, or resistant by referring to an interpretative chart. 
The definition of these categories is as follows [29]: 
Susceptible: A category that implies that an infection due to the isolate may be 
appropriately treated with the dosage of an antimicrobial agent recommended for 
that type of infection and infecting species. 
Intermediate: A category that implies that an i!1fection due to the isolate may be 
appropriately treated in body sites where the drugs are physiologically 
concentrated or when a high d<?sage of the drug can be used; also indicates a 
"buffer zone" that should prevent small, uncontrolled, technical factors from 
causing major discrepancies in interpretations. 
Resistant: Resistant isolates are not inhibited by the usually achievable 
concentrations of the agent with normal dosage schedules and/or fall in the range 
where specific resistance mechanisms are likely (e.g., beta-lactamases), and 
clinical efficacy has not been reliable in treatment studies. 
In order to categorize strains as susceptible, intermediate or resistant, breakpoint 
antibiotic concentrations are used. A breakpoint is a discriminating MIC value 
used to define isolates as susceptible, intermediate or resistant. 
Three features of both the antimicrobial agent and the . pathogen must be 
considered when deciding upon a breakpoint: (i) the bacterial population 
distribution of MIC values; (ii) pharmacological properties of the antimicrobial; 
and (iii) clinical outcome data [26]. 
The rationale of the interpretative charts assumes that the relationship between 
the diameter of the zone and the MICs is known. In order to define this 
relationship, scattergram plots are generated for each of the 
antimicrobial/organism combinations studied. 
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The MIC values plotted_ against matching zone diameters result m a 
' scattergram', from which the line of best fit (regression line) is calculated. Zone 
diameters, equivalent to the breakpoints, to separate the different categories, 
susceptible, intermediate or resistant are determined from this linear relationship 
[5 , 29]. 
All the susceptibility-testing techniques described above reqmre the pnor 
isolation and identification of the organism, and hence the result is often not 
available until 2 days later. There is also no international agreement on 
breakpoints for interpretation of antimicrobial susceptibility tests. 
To increase the speed and reliability of resistance testing, the use of a genotypic . 
approach has been advocated recently [7] , and numerous DNA-based assays 
have been developed for detection of bacterial resistance genes. 
Bergeron and Ouellette [7] highlighted the limitations of this approach. For 
example the presence of a resistance gene may not always be indicative of 
resistant bacteria, and conversely, if a gene coding for resistance to an 
antimicrobial is not detected, it may not mean that the bacteria are susceptible to 
that particular agent. Further clinical studies will be required to validate the 
genotypic approach to testing for resistance, 
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THE STUDY: 
Materials and methods 
Bacterial strains: 
One hundred and seventy two clinical isolates of Acinetobacter spp. from the 
Groote Schuur Hospital region, Cape Town, were collected both retrospectively 
(Feb 1998 to Dec 2000) and during the evaluation period (Jan to Jun 2001 ). 
Only one isolate per patient was included; however organisms isolated from the 
same patient on more than one occasion were included if these repeat isolates 
showed different antimicrobial susceptibility patterns. This approach is based on 
a study [ 11 ], which showed that the use of antimicrobial susceptibility patterns to 
group similar Acinetobacter isolates correlates well with other typing and 
epidemiological data. 
Bacterial identifications: 
Phenotypic identification of the genus Acinetobacter was based on the following 
criteria [18]: gram-negative coccoid rods, oxidase negative, catalase positive, 
non-fermenting and strict aerobes. 
Phenotypic identification of Acinetobacters to the species level was performed 
utilising simplified phenotypic tests (Table 1 ), based on tests described by 
Gerner-Smidt et al and others [16, 34, 39]. 
Tests for growth at 35°C and 44°C were performed using Mueller-Hinton agar 
(Biolab.Merk) utilising an incubator. Sheep blood (5%) agar plates were used to 
detect haemolysis, glucose oxidation was determined in a 1 % dextrose medium, 
and citrate utilisation was determined using Simmons citrate medium (Oxoid) . 
The above tests were incubated at 35°C, and results read after 18 to 24 hours 
and again after 48 hours to confirm the negative results. 
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Table 1. Phenotypic characteristics of Acinetobacter spp. 
A. calcoaceticus A.baumanii A. haemolyticus A.junii 
Growth at 37°C 100 100 100 100 
Growth at 44 ° C 0 100 0 0 
Acid from . 100 95 52 0 
glucose 
Sheep blood 0 0 100 0 
agar 
(haemolvsis) ' 
Citrate 100 100 91 82 
utilisation 
* The numbers represent the % positive.strains for each test. 
+ Data are from the Manual of Clinical Microbiology, ih edition, p-542 [39]. 
A summary of how the species of Acinetobacter were identified: 
• Glucose oxidizing, non-haemolytic strains with growth at 44°C were 
identified as A. baumanii. 
• Glucose oxidizing, non-haemolytic strains with no growth at 44°C 
were identified as A.calcoaceticus. 
• Glucose negative, non-haemolytic and citrate positive were identified 
as A.junii. 
• Glucose negative, non-haemolytic and citrate negative were identified 
as A. lwoffii. 
• Haemolytic strains were identified as A.haemolyticus 
NB . Ajohnsonii will not be identified by this scheme, because of its inability 








After the bacterial identifications were confirmed, the isolates were stored on 
Dorset egg media at room temperature. At a later stage the antimicrobial 
susceptibilities were tested in batches. 
Antimicrobial agents: 
For disk diffusion tests CPIM (30µg) , CTAZ (30µg) and TMP-SULFA (1.25 
µg/23 .75µg) were obtained from Oxoid, and PIP-TAZO (lOOµg/lOµg) was 
obtained from Mast diagnostics. For MIC determinations CPIM and CT AZ 
E-strips were obtained from AB Biodisk Siona, Sweden, TMP-SULF A 
reference powders were obtained from Mast diagnostics, and PIP-T AZO 
reference powders were obtained from Wyeth-Ayerst. 
Antimicrobial susceptibility testing: 
Antimicrobial susceptibility testing was performed as recommended by the 
NCCLS [28, 30]. 
The disk diffusion test was performed, using MH agar (Biolab Merk), to 
determine the zone size diameters for CPIM, CT AZ, TMP-SULF A and PIP-
T AZO. The MIC was determined by both the agar dilution method for 
TMP-SULF A and PIP-T AZO, and the E-test for CPIM and CT AZ, using 
MH agar (Biolab Merk) in both methods. 
[al Disk diffusion tests: 
Inoculum preparation: 
A direct broth suspension of isolated colonies selected from a 16 to 18 hours 
growth on an agar plate was performed, using Mueller-Hinton broth. The 
suspension was then adjusted to match a 0.5 McFarland turbidity standard by 
the unaided eye. 
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Inoculation of test plates: 
A sterile cotton swab was dipped into th~ adjusted suspension, rotated and 
pressed to the inside · of the test tube to remov~ excess fluid from the swab. 
The dried surface of a Mueller-Hinton agar plate was then inoculated with 
the swab using a rotating device. 
Application of the antimicrobial disks: 
The antimicrobial disks (viz. CPIM, CTAZ, TMP-SULFA, and PIP-TAZO) 
were dispensed onto the inoculated agar using a dispensing apparatus, 
making sure that they are no closer than 24mm from centre to centre. Plates 
were inverted and placed in an incubator set at 3 5°C. 
Reading plates: 
After 16 to 18 hours each plate was examined to check that the inoculum 
was correct (i.e. semiconfluent). The zones of inhibition were measured to 
the nearest millimetre, using sliding calipers. For TMP-SULFA slight 
growth (20% or less of the lawn of growth) was disregarded, and the more 
obvious margin was measured. · 
The zone diameters were recorded in millimetres for each antimicrobial agent 
tested against each isolate. 
[bl Agar dilution method: 
The agar dilution method was used"'to determine the MIC for TMP-SULF A 
and PIP-TAZO. 
Our intention was to also use this method to determine the MIC for CPIM 
and CT AZ, but the reference powders of CPIM and CT AZ were not 
obtainable, hence it was decided to perform the E-test to determine their 
MICs. 
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Weighing antimicrobial powders: 
The following formula [30] was used to determine the amount of reference 
powder needed for the preparation of the antimicrobial stock solution: 
Weight (mg) = Volume (ml) x Concentration (µg/ml) 
Assay potency (µg/ml) 
Preparation of stock solutions: 
The procedure for TMP-SULF A an_d PIP-T AZO stock solution preparation, 
from the reference powder, is shown in Table 2. 
Table 2. TMP-SULF A and PIP-T AZO stock solutions preparation. 
Concentration Dilution 





Trimethoprim 0.05 mol/L Water heated 320 0.016 to 32 
hydrochloric to 35°C in a 
acid (10% water bath. 
final volume). 
Sulfamethoxazole Half volume Water 6080 0.29 to 608 
hot water and 
.. 
mm1mum 
amount of 2.5 
mol/L NaOH 
to dissolve. 
Piperacillin - Water Water 5120 0.125 to 512 
sodium 




NB. Piperacillin monohydrate powder supplied by Wyeth-Ayerst will only 
dissolve in pure methanol, and as soon as water (hot or cold) is added it will 
precipitate. Wyeth-Ayerst has recommended the use of piperacillin-sodium 
powder, which is soluble in water, for MIC determination by the agar dilution 
method. 
The stock solutions were dispensed in aliquots into sterile polystyrene test 
tubes, and then stored at -20°C, until used. 
Preparing agar dilution p_lates: 
TMP-SULFA was tested at a ratio of 1/ 19 (0.016/0.29µg/ml to 32/608µg/ml) 
and PIP-TAZO was tested at 0.125/4µg/ml to 512/4µg/ml. Tazobactam 
concentration was constant at 4µg/ml throughout the dilutions of piperacillin. 
Mueller-Hinton agar (MI-I-agar) was used for the agar dilution method, with a 
final volume of 20ml per 9cm petri dish plates to give an agar depth of 
approximately 4mm. 
The appropriate dilutions of the antimicrobial agent were added to molten 
Mueller-Hinton agar that had been allowed to equilibrate in a water bath set at 
50°C. 
The agar and antimicrobial dilution were mixed thoroughly before being 
poured into 9cm petri dish plates. The agar was allowed to cool and solidify at 
room temperature, making sure no bubbles were formed in this process. 
The plates were then sealed in plastic bags and stored at 4-8°C for no longer 
than 5 days. 
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Growth control plates: 
Antimicrobial free Mueller-Hinton agar plates were prepared for use as growth 
control plates. 
Preparing the inocu/um: 
Bacterial suspensions adjusted to match a 0.5 McFarland standard were 
prepared as described earlier for the disk susceptibility technique. These 
adjusted suspensions contain approximately 1 to 2 X 10
8 CFU/ml . This was 
further diluted 1: 10 in sterile normal saline to obtain the desired inoculum 
concentration of 107 CFU/ml. 
Inoculating the agar dilution plates: 
The agar plates were inoculated with a semi-~utomated replicating device. 
An aliquot (100µ1) of the adjusted and diluted bacterial suspension was 
transferred to the corresponding well in the replicator inoculum block. The 
agar plates were marked for orientation. 
Approximately 1 to 2µ1 was transferred from each well in the inoculum block 
onto the agar surface by the replicating device. 
A growth control plate was inoculated first and then the agar dilution plates 
were inoculated starting with the lowest antimicrobial concentration. A second 
growth control plate was included at the end to ensure that there was no 
contamination or significant antimicrobial carryover during the inoculating 
process. The first growth control plate ~as used to check that the organisms 
were viable and could grow on Mueller-Hinton agar plates . 
The inoculated plates were left at room temperature till the inoculum spots 
were absorbed into the agar, and then they were inverted and incubated at 3 5° 
C for 18 to 24 hours. 
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Determining agar dilution end points: 
The plates were read against a dark background, with an incident light 
source. The MIC was recorded· as the lowest concentration of antimicrobial 
agent that completely inhibited growth. A single ~olony or a faint haze was 
disregarded. 
[cl The E-test method: 
The E-test method (E-test AB Biodisk, Siona, Sweden) was used for MIC 
determination of cefepime and ceftazidime. 
Cefepime E-test strips have an antimicrobial concentration range of 0.002 to 
32 µg/ml , and ceftazidime E-test strips have an antimicrobial concentration 
range of 0.016 to 256 µg/ml. 
The MIC determination was performed as recommended by the 
manufacturer. 
Inoculum preparation: 
Bacterial suspensions adjusted to match a 0.5 McFarland standard were 
prepared as described earlier for the disk susceptibility technique. 
Inoculation: 
Mueller-Hinton agar was used based on the NCCLS recommendations. A 
sterile swab was dipped into the inoculum suspension, and excess fluid 
removed by pressing the swab against the inside wall of the test tube. Then 
the entire surface of a 9cm petri dish plate was swabbed three times, rotating 
the plate approximately 90 degrees each time, to ensure an even distribution 
of the inoculum. 
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.. 
Application of the £-test strips: 
The E-test strip was applied manually to a dry inoculated MR-agar, making 
sure that the whole length of the strip was in complete contact with the agar 
surface. If any, air pockets were removed by pressing gently on the strip 
with forceps, moving from the minimum concentration upwards. 
Two E-test strips were applied to a single 9cm agar plate, in parallel, but 
with the gradient antimicrobial concentrations'running in opposite directions. 
Incubation: 
Agar plates were incubated immediately at 3 5°C for 18 to 20 hours. 
Reading the MIC: 
The MIC was determined at the point of intersection between the inhibition 
ellipse edge and the E-test strip. When growth occurred along the strip, i.e. 
no inhibition ellipse seen, the MIC was reported as "greater than" (>32µg/ml 
for CPIM and >256µg/ml for CTAZ). When-the inhibition ellipse is below 
the strip, i.e. the zone edge does not intercept· the strip; the MIC was 
reported as "less than" (<0.002µg/ml for CPIM and <0.016µg/ml for 
CTAZ). 
NB. The MIC was always read at the point of complete inhibition of all 
growth. Hazy growth and isolated colonies were regarded as growth. 
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Quality control procedures: 
[a] For the disk diffusion tests the following, reference strains were included 








For TMP-SULFA, the following reference strain was included in each run: 
Escherichia coli ATCC 25922 
For PIP-T AZO, the following reference strains were included in each run: 
Escherichia coli ATCC 35218 
[ c] For the E-tests for CPIM and CT AZ, the following reference strains were 





The Acinetobacter isolates were tested in batches of 18 organisms per run. Zone 
size diameters and MICs were deterrrxned simultaneously, and quality control 
reference strains were included with each run. 
The results of each run were only accepted when the quality control reference 
strains results were within the acceptable ranges recommended by NCCLS 
(shown in Tables 4 and 5 in appendix). [31]. 
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Regression line determination: 
The MIC values, expressed logaritnmically, were _plotted against matching zone 
diameters resulting in a "scattergram". The regression line was calculated, 
correlating MI Cs and zone diameters of inhibiti.on. These calculations excluded 
undefined measurements ( such as no zone of inhibition or off-scale MI Cs) [29] . 
The Pearson coefficient of correlation was used as a measure of the linear 
relationship obtained between the MIC and zone diameters of inhibition for each 
antimicrobial agent tested [23]. 
The use of a regression line allows the determination of the equivalent zone size 
diameter for each MIC, however interpretative zone size diameters can only be 
established when the MIC breakpoints have be.~n selected [l]. The MIC 
breakpoints used in the study were those selected by the NCCLS for 
Acinetobacter spp. [31]. 
REULTS: 
Bacterial strains tested: 
One hundred and seventy two Acinetobacter isolates were included in this study, 
of which 160 were tested for their antimicrobial susceptibilities to CPIM, CT AZ, 
TMP-SULFA and PIP-TAZO. The distributions of species were as follows 
(Figure 1): A.baumanii (155 [90%]), A.haemolyticus (7 [4.1%]), A.junii (5 
[3%]), A.lwoffii (4 [2.3%]) and A:ca!coaceticus (1 [0.6%]). 
The Acinetobacter isolates included in this study (both those collected 
retrospectively and during the study period) were mostly isolated from blood 
culture and tracheal aspirate specimens from ICU patients, and they do not 
reflect the overall incidence and prevalence of Acinetobacter spp. in the Groote 













The distribution of Acinetobacter species 
Phenotypic identification and antimicrobial susceptibility testing results: 
Table 3. (see appendix), shows the ph·enotypic identification and susceptibility 
testing results for the individual Acinetobacter isolates. 
Controls: 
The results of the control reference strains were witJ:iin the acceptable ranges 
recommended by NCCLS [31] in all 9 testing runs . There were no runs rejected 
and repeated. Table 6. (see appendix), shows the results obtained for each 
control reference strain in each testing run. 
For the acceptable ranges recommended by the NCCLS for these control 
reference strains see Tables 4 and 5 (in appendix) . 
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Antimicrobial susceptibility interpretation: 
The antimicrobial susceptibility testing results (zone diameters and MICs) were 
interpreted as sensitive, intermediate and resistant by referring to the NCCLS 
interpretative standards for Acinetobacter spp . (Table 7.) [31]. 
Table 7. The NCCLS zone diameter interpretative standards and the equivalent 
MIC breakpoints for Acinetobacter spp. 
Disk 
Antimicrobial MIC breakpoint content Interpretative zone diameter (mm) 
agent (u2/ml) (µ~) 
R s R I 
CTAZ 232 s:;8 30 s:; 14 15-17 
CPIM 232 s:;8 30 s:; 14 15-17 
TMP-SULFA 28/152 s:;2/38 1.25/23 . 75 :s; lO 11-15 
PIP-TAZO 2 128/4 s:; 16/4 100/10 s:; 17 18-20 
R= Resistant, I= Intermediate, and S= Sensitive. 
Agreements and errors: 
Disk diffusion and MIC results were deemed to be in agreement if the test results 
were within the same susceptibility category, and the errors were defined as in 
the NCCLS M23-A2 publication [29]. 
The errors were ranked as follows : very major error, false susceptible result 
produced by the disk diffusion test; major error, false resistant result produced 
by the disk diffusion test; and minor error, when one test result is intermediate 







Table 8. summarizes all the interpretative errors of the disk diffusion test results, 
(interpreted using the NCCLS zone diameter interpretative standards), compared 
to the MIC result, for each antimicrobial agent tested. 
Table 8. Summary of the interpretative errors for the tested antimicrobial 
agents. 
Antimicrobial agents Interpretative errors 
tested 
Very major Major Minor 
CPIM 13 (8%) 0 63 (39.4%) 
CTAZ 0 0 20 (12 .5%) 
TMP-SULFA 0 4 (2.5%) 23 (14.4%) 
PIP-TAZO 3 (1.9%) 1 (0.63%) 49 (31%) 
The disk susceptibility for CT AZ and. TMP-SULF A showed no very major 
errors. In addition CT AZ showed no major errors either, but TMP-SULF A 
showed 4 major errors. CPIM showed 13 (8%) very major errors and no major 
errors, and PIP-TAZO showed 3 (1.9%) very major errors and one major error. 
Minor interpretative errors were frequent with all the antimicrobial agents tested. 
Regression line determination: 
• 
Figures 2 to 5 (see appendix) present the regression lines calculated for CPIM, 
CT AZ, TMP-SULF A, and PIP-T AZO respectively. The NCCLS breakpoints 
and zone size criteria, as well as the zone size diameters determined in the study, 
are indicated on each figure . 
The regression line for each antimicrobial/organism was calculated excluding the 
undefined measurements (such as no zone of inhibition or off-scale MIC), 
(Table 9). 
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Table 9. The number of Acinetobacter isolates included in the regression 
line calculation for each antimicrobial agent tested. 
Antimicrobial Number of Acinetobacter isolates 






The Pearson coefficient of correlation calculated for each antimicrobial agent is 
as follows : 
CPIM = - 0.72868 
CTAZ = - 0.70981 
TMP-SULFA = - 0. 76087 
PIP-TAZO = - 0.40866 
For CPIM, CTAZ and TMP-SULFA there is a strong negative relationship 
between the MICs and zone size diameters. 
For PIP-T AZO the relationship is moderate. 
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DISCUSSION: 
The aim of the study is to evaluate the appropriateness/validity of the NCCLS 
zone size criteria for Acinetobacter spp. in an effort to enhance the reliability of 
in-vitro antimicrobial susceptibility results fo.r Acinetobacter spp. 
To our knowledge there were no published reports on the validity of the NCCLS 
breakpoints for Acinetobacter spp. 
An increased number of nosocomial Acinetobacter spp. are found to be resistant 
to multiple antimicrobial agents [8, 9, 13 , 25 , 41] , which may indicate that there 
is a significant change in their population distributron [ 1]. 
Breakpoints are determined based on formulae that take into account several 
pharmacokinetic factors . The final adjustments to the selected breakpoint, are 
influenced by the bacterial population distribution, according to their 
susceptibility patterns to the antimicrobial agent studied. 
Once the breakpoints are determined, dilution and disk diffusion tests are 
. 
performed on at least 500 isolates. The data is then displayed as a scattergram 
with zone diameters on one axis and the MICs on another. From this 
scattergram the regression line is calculated representing the relationship 
between the zone sizes and the ·MICs. This relationship allows the equivalent 
zone size to a selected MIC breakpoint to be derived [l , 5, 29]. 
In practice, the proposed breakpoints are simply adjusted until the number of 
false sensitive disk diffusion test results ( very major discrepancies) and false 
resistant disk tests (major discrepancies) are held to a minimum. 
Minor discrepancies are also considered in these determinations [29]. 
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In the event of a change in the bacterial population distribution, when less 
susceptible and/or resistant strains develop to an antimjcrobial agent whose 
breakpoints were determined when only susceptible strains were available, the 
interpretative criteria may need reassessment. 
When evaluating disk susceptibility tests, . based on NCCLS guidelines [29] , the 
discrepancy rates are considered acceptable if very major discrepancy rates do 
not exceed 1.5%, and major discrepancies do not exceed 3%, when calculated 
based on all isolates. These acceptable. discrepancy rates are recommended for 
unselected clinical isolates, as is the case· in this study. 
This study has shown that CPIM and PIP-I AZO disk susceptibility testing has 
resulted in unacceptably high numbers (8% and 1.9% respectively) of very major 
errors (i .e. exceeding 1.5%). 
None of the tested antimicrobial agents has resulted in unacceptable numbers of 
major errors (i .e. exceeding 3%). 
It was noted that all the "very major" and "major" errors occurred when testing 
A.baumanii. This could be due to the fact that 90% of the Acinetobacter spp . 
tested in trus study belonged to the species A. baumanii. 
Minor errors were frequent with all the tested antimicrobial agents. 
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Regression line analysis: 
For figures 2 to 5 see appendix. 
[i] For CPIM, Figure 2. 
The results obtained for CPIM show that the NCCLS zone size criteria are 
consistently smaller than those determined in this study, leading to increased 
• 
false sensitive reporting. This explains the unacceptable rate of very major errors 
reported for CPIM disk susceptibility testing in the study. 
[ii] For CTAZ, Figure 3. 
The results of this study were in agreement with the NCCLS zone size criteria. 
[iii] For TMP-SULFA, Figure 4. 
The results obtained for TMP-SULF A show that the NCCLS zone size criteria 
are consistently larger than those determined in this study. This does not explain 
the reason for 4 (2.5%) major errors (false resistant result by disk diffusion 
testing) reported in the study. Three of these isolates with major errors had no 
zone of inhibition around the TMP-SULF A disks, but they were sensitive by the 
MIC testing method. This discrepancy between disk diffusion and MIC results 
could be related to a particular lot of Mueller-Hinton agar [ 42]. This warrants 
further investigation. 
[iv] For PIP-TAZO, Figure 5. 
The results of this study were in agreement with the NCCLS zone size criteria. 
The unacceptable rate of very major errors reported for PIP-T AZO disk 
diffusion susceptibility testing in the study, may indicate a change in PIP-T AZO 
susceptibility pattern in this bacterial population. Such a change may necessitate 
a reassessment of the selected breakpoints for PIP-T AZO. 
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The number of Acinetobacter isolates (160) tested in this study was not sufficient 
to study the bacterial population distribution. Furthermore the study suffered 
from a further limitation. Calculation of the regression line for each 
antimicrobial/organism excluded the undefined measurements (such as no zone 
of inhibition or off-scale MIC results), resulting in further isolates being 
excluded, e.g. for TMP-SULF A only 68 isolates out of 160 tested were included 
for the regression line calculation. 
Despite these limitations, this study reveals that a reassessment of the current 
NCCLS breakpoints and zone size criteria for Acinetobacter spp . may be 
necessary for cefepime and piperacillin/tazobactam in order to continue 
providing reliable in-vitro antimicrobial susceptibility testing. 
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Figure 4. Regression line correlating MICs and zone diameters for trimethoprim-sulfamethoxazole (68 
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